What does the evidence say about Phosphatidylserine Cognition Randomized Trial?

The current Migaku evidence database contains 2 reusable source documents for Phosphatidylserine Cognition Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - This study aimed to evaluate the effects of PS on core symptoms and associated behavioral problems in children with ADHD. [Shen Z (2026); evidence level 4] - In contrast, the PS group demonstrated significant reductions in internalizing (M = 1.83, SD = 3.28, p < 0.05, d = 0.56) and externalizing behaviors (M = 3.38, SD = 5.20, p < 0.05, d = 0.65), whereas the atomoxetine group improved only in externalizing behaviors (M = 2.54, SD = 5.42, p < 0.05, d = 0.47). [Shen Z (2026); evidence level 4] - Phosphatidylserine was not associated with significant improvements in core ADHD symptoms but was associated with reductions in internalizing and externalizing behavioral problems, particularly in reducing aggression. [Shen Z (2026); evidence level 4] - Attention Deficit Hyperactivity Disorder (ADHD) is a common neurodevelopmental disorder in children, characterized by attention deficit, hyperactivity, and various internalizing and externalizing behavioral problems. [Shen Z (2026); evidence level 4] - Phosphatidylserine Supplementation on Psychomotor Speed among Healthy Adults with Subjective Cognitive Declines [Phosphatidylserine Supplementation on Psychomotor Speed among Healthy Adults with Subjective Cognitive Declines (2025); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.